Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Published Online: 2018-10-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Ana Arance•Carmen Loquai•Caroline Dutriaux•Caroline Robert•Claus Garbe•Dirk Schadendorf•Gabriella Liszkay•Helen J Gogas•Ivana Krajsova•Jan Willem B de Groot•Keith T Flaherty•Laure A Moutouh-de Parseval•Mario Mandala•Michael D Pickard•Naoya Yamazaki•Paolo A Ascierto•Ralf Gutzmer•Reinhard Dummer•Vanna Chiarion Sileni•Victor Sandor
